GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

GSK is 'well positioned' to deal with the ... tariff on all imported US goods earlier this month but exempted pharmaceutical products from those duties. But the US Government began investigations ...

British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread ...

GSK has posted a solid set of financial results in the first quarter of this year and said it is not too worried about the financial impact of potential pharma ... the five FDA product approvals ...

British drugmaker GSK insisted it was “well positioned” to respond ... Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

GlaxoSmithKline ( ($GSK) ) has shared an update. On May 7, 2025, GSK plc announced the purchase of 687,081 of its own ordinary shares at prices ...